Takashi Imada

Discovery of a Novel, Potent, and Orally Active Nonpeptide Antagonist of the Human Luteinizing Hormone-Releasing Hormone (LHRH) Receptor

Nobuo Cho, Masataka Harada, Toshihiro Imaeda et al. · Journal of Medicinal Chemistry · 1998 · 126 citations · Full text

Human Growth, Altmetric Attention Score, Peptide Science +23

Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds

Masanori Okaniwa, Masaaki Hirose, Takashi Imada et al. · Journal of Medicinal Chemistry · 2012 · 76 citations

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki et al. · Science Advances · 2019 · 67 citations · Full text

Discovery of [<i>cis</i>-3-({(5<i>R</i>)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1<i>H</i>-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5<i>H</i>)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Mitsunori Kono, Atsuko Ochida, Tsuneo Oda et al. · Journal of Medicinal Chemistry · 2018 · 62 citations

Pharmacotherapy, Pharmaceutical Chemistry, Pre-clinical Pharmacology +16

Cyclic Hexapeptide Endothelin Receptor Antagonists Highly Potent for Both Receptor Subtypes ETA and ETB

Takashi Kikuchi, Tetsuya Ohtaki, Akira Kawata et al. · Biochemical and Biophysical Research Communications · 1994 · 48 citations

Molecular Pharmacology, Functional Selectivity, Medicine +8